Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Rheumatoid arthritis in 2014

Exciting times for RA research

Nature Reviews Rheumatology volume 11, pages 69–70 (2015)Cite this article

Subjects

2014 saw the emergence of a novel rheumatoid arthritis therapy to rival methotrexate, as well as advances in our understanding of mouse T-cell biology and of the cross-talk between the nervous system and the immune system. How will these advances affect the future of rheumatoid arthritis research and therapy?

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: 2014 RA research.

References

  1. Maini, R. et al. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354, 1932–1939 (1999).

    Article  CAS  Google Scholar 

  2. Smolen, J. S., Aletaha, D., Koeller, M., Weisman, M. H. & Emery, P. New therapies for treatment of rheumatoid arthritis. Lancet 370, 1861–1874 (2007).

    Article  CAS  Google Scholar 

  3. Stangenberg, L. et al. Denervation protects limbs from inflammatory arthritis via an impact on the microvasculature. Proc. Natl Acad. Sci. USA 111, 11419–11424 (2014).

    Article  CAS  Google Scholar 

  4. Komatsu, N. et al. Pathogenic conversion of Foxp3+ T cells into TH17 cells in autoimmune arthritis. Nat. Med. 20, 62–68 (2014).

    Article  CAS  Google Scholar 

  5. Lee, E. B. et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 370, 2377–2386 (2014).

    Article  Google Scholar 

  6. Sakaguchi, S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22, 531–562 (2004).

    Article  CAS  Google Scholar 

  7. Thiolat, A. et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol. 66, 273–283 (2014).

    Article  CAS  Google Scholar 

  8. Kremer, J. M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349, 1907–1915 (2003).

    Article  CAS  Google Scholar 

  9. Edwards, J. C. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350, 2572–2581 (2004).

    Article  CAS  Google Scholar 

  10. Emery, P. et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 39, 655–665 (2000).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, NIHR Leeds, Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK

    Paul Emery

Authors
  1. Paul Emery
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paul Emery.

Ethics declarations

Competing interests

The author declares that he has undertaken clinical trials and acted as a consultant for Abbott/Abbvie, Bristol Myers Squibb, Lilly, MSD, Novartis, Pfizer, Roche, Samsung, Takeda and UCB.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Emery, P. Exciting times for RA research. Nat Rev Rheumatol 11, 69–70 (2015). https://doi.org/10.1038/nrrheum.2014.216

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2014.216

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing